Abeona Acquires APT-1011 Assets in $20 Million Stock Deal
Abeona acquired substantially all assets related to Ellodi’s APT-1011 oral drug candidate, issuing 4,494,383 shares valued at $20 million. The deal also includes up to $60 million in regulatory and sales milestones, plus tiered sales royalties.
Abeona Therapeutics acquired substantially all assets related to Ellodi Pharmaceuticals' APT-1011, an oral drug candidate for eosinophilic esophagitis, issuing Ellodi 4,494,383 shares valued at $20 million and agreeing to up to $60 million in regulatory and sales milestones plus tiered sales royalt…